MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Operating Cycle 2011-2026 | ANIX
Annual Operating Cycle Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 275 | - | - | - | 97.1 | - | - | - | - | 39.8 | 164 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 275 | 39.8 | 144 |
Quarterly Operating Cycle Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 55.6 | 4.18 | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 24.3 | 12.1 | - | 25.2 | 38.6 | - | - | 27.8 | 27.8 | - | - | - | - | - | 0.22 | - | - | - | - | 15.9 | 30.7 | 16.5 | 3.75 K | - | - | - | 0.71 | 912 | - | - | - | 0.54 | 1.39 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.75 K | 0.22 | 276 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
1.2 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
161 | $ 117.79 | 3.44 % | $ 35.8 B | USA |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
97.9 | $ 25.76 | 3.75 % | $ 716 M | USA |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
Danaher Corporation
DHR
|
143 | $ 197.13 | 3.2 % | $ 140 B | USA |
 |
Enzo Biochem
ENZ
|
206 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
91.7 | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 16.46 | 3.46 % | $ 498 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 18.77 | 6.23 % | $ 1 B | USA |
 |
Guardant Health
GH
|
128 | $ 98.12 | 5.17 % | $ 12.3 B | USA |
 |
DexCom
DXCM
|
202 | $ 65.04 | 3.05 % | $ 25.4 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
275 | $ 16.49 | 2.49 % | $ 177 M |  China |
 |
Co-Diagnostics
CODX
|
1.79 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 111.47 | 4.02 % | $ 9.19 B |  Irlanda |
 |
Illumina
ILMN
|
198 | $ 131.01 | 3.61 % | $ 20.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 175.27 | 2.78 % | $ 30.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
71.8 | $ 272.99 | 1.42 % | $ 22.7 B | USA |
 |
Lantheus Holdings
LNTH
|
121 | $ 79.33 | 1.6 % | $ 5.35 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 178.81 | 5.42 % | $ 8.86 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 522.44 | 2.74 % | $ 15.1 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K |  Israel |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 314.35 | 3.49 % | $ 27.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
95.1 | $ 4.91 | 3.61 % | $ 455 M | USA |
 |
NeoGenomics
NEO
|
102 | $ 8.46 | 4.96 % | $ 1.08 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 14.78 | 1.69 % | $ 1.92 B | USA |
 |
Neogen Corporation
NEOG
|
213 | $ 10.59 | 6.06 % | $ 2.3 B | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Natera
NTRA
|
81.5 | $ 217.44 | 3.9 % | $ 21.4 B | USA |
 |
Pacific Biosciences of California
PACB
|
244 | $ 1.53 | 6.25 % | $ 459 M | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Quotient Limited
QTNT
|
432 | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Precipio
PRPO
|
43.8 | $ 28.84 | 1.19 % | $ 46.3 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 6.72 | 8.91 % | $ 398 M | USA |
 |
QIAGEN N.V.
QGEN
|
172 | - | - | $ 10.6 B |  Niderland |
 |
Biomerica
BMRA
|
204 | $ 2.18 | 0.93 % | $ 5.01 M | USA |
 |
BioNano Genomics
BNGO
|
315 | $ 1.16 | -0.85 % | $ 6.32 M | USA |
 |
Interpace Biosciences
IDXG
|
96 | $ 2.0 | 1.27 % | $ 8.85 M | USA |